Short communication · 2016
Conference abstractPublished 20 Sep 2018
The Role of Dobutamine Dose on the Cardiac Parameters
The University of Burdwan, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objectives: The report presents the effects of dobutamine dose on the cardiac parameters such as blood pressures (basal, systolic, diastolic & maximum), heart rates (basal, peak & maximum), baseline cardiac ejection fraction, ejection fraction on dobutamine dose. Background: There is a little literature about the effects of dobutamine dose on the cardiac parameters. Materials and Methods: The effects of dobutamine dose on the cardiac parameters have been examined based on a real echocardiography stress data set, collected at University of California, Los Angeles on 558 patients with 31 explanatory variables/ factors. The distribution of the considered cardiac parameters is gamma with non-constant variance. So, they have been analyzed by joint generalized linear gamma models. Results: The mean basal blood pressure (BBP) decreases as the double product of maximum heart rate (MHR) & maximum blood pressure (MBP) at dobutamine dose (DPMAXDO) (P<0.001) increases, while the variance of BBP increases as the DPMAXDO (P<0.001) increases. The mean systolic blood pressure (SBP) increases as the dobutamine dose (DOSE) (P=0.032) increases, while the mean SBP increases as the DPMAXDO (P<0.001) decreases. The mean MBP increases as the DPMAXDO (P<0.001) increases. The mean baseline cardiac ejection fraction (BEF) decreases as the DOSE (P=0.025) increases. The mean ejection fraction on dobutamine dose (DOBEF) increases as the DOSE (P=0.011) increases, while the variance of DOBEF increases as the dobutamine dose at maximum double product (DOBDOSE) (P=0.001) decreases. The mean basal heart rate (BHR) increases as the DPMAXDO (P<0.001), or DOBDOSE (P=0.074) decreases. The mean peak heart rate (PHR), or maximum heart rate (MHR) increases as the DPMAXDO (P<0.001) increases, while the variance of PHR, (MHR) increases as the DOBDOSE (P<0.001) decreases (increases). On the other hand, dobutamine dose is associated with many cardiac parameters such as SBP, MBP, new myocardial infraction (new MI), history of MI (hxofMI)etc. Conclusions: Only the dobutamine dose effects are observed on SBP, MBP, DOBEF, newMI, histMI, etc, while the joint effects of dobutamine (DPMAXDO and DOBDOSE) are observed on each cardiac parameters. The results are new inputs in the dobutamine dose study literature.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 14 Nov 2016
From ECGs, various cancers and their biochemical information were detected. In the presence of cancer and myocardial ischemia we found significant reduction of Taurine in various cancer tissues & in the Lyme disease infected part of the heart where Cardiac Troponin I & ANP is markedly increased in Atrial Fibrillation ECGs. Optimal dose of Taurine was found to reduce cancer parameter and improve myocardial function, Alzheimer related factors significantly
Research article · 20 May 2017
Determinants of Cardiac Ejection Fraction for the Patients with Dobutamine Stress Echocardiography
Article · 30 Sep 2024
The Role of Dobutamine in Heart Failure and Cardiogenic Shock: Benefits, Risks and Future Directions
Research article · 2017
Differentiation between Clinical and Academic Myocardial Viability. Complementary Myocardial Perfusion SPECT and Low Dose Dobutamine Echocardiography Role vs. Histopathological Study
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectCardiology
- BylineArticles whose byline prints “Rabindra Nath Das”
